Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 5/20 | 0.50 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.44 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13185669 | 0.87 | KDM4E (0.61) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL13992613 | 0.82 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL13994778 | 0.80 | CDC7 (0.61) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL2200209 | 0.80 | ERN1 (0.45) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL7018973 | 0.79 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL5793863 | 0.78 | AKT3 (0.61) | — | |
| SCHEMBL2492178 | 0.78 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL13994818 | 0.77 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL622871 | 0.77 | CDC7 (0.63) | HDAC3HDAC4HDAC1HDAC6CDC7 | |
| SCHEMBL17201672 | 0.77 | ERN1 (0.48) | HDAC3HDAC4HDAC1HDAC6CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7790716-B2 | fatty acid biosynthesis inhibitors such as E)-3-(6-aminopyridin-3-yl)-N-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)acrylamide, used fro the treatment of bacterial infections; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090275572-A1 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557125-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-07-07 | — | — | US | disclosed |
| US-7048926-B2 | Methods of agonizing and antagonizing FabK | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
| US-20040053814-A1 | Methods of agonizing and antagonizing FabK | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053814-A1 | Methods of agonizing and antagonizing FabK | ANTXR2, FPR3, BDKRB2 | HDAC3 1240/4885HDAC4 2294/4885HDAC1 2115/4885 |
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | HDAC3 804/4885HDAC4 1047/4885HDAC1 87/4885 |
| US-20090275572-A1 | FAB I INHIBITORS | SERPINB1, TFPI, TFPI2 | HDAC3 804/4885HDAC4 1047/4885HDAC1 87/4885 |
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | HDAC3 804/4885HDAC4 1047/4885HDAC1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.